KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
| | |

KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

On Jul. 7, 2025, KalVista Pharmaceuticals announced that the U.S. Food and Drug Administration(FDA) has approved EKTERLY® (sebetralstat),…

NIH will reinstate 900 grants in response to court order
| | | | | | | | | | | | | | | | | | | | |

NIH will reinstate 900 grants in response to court order

On Jun. 25, 2025, the National Institutes of Health (NIH) moved to reinstate about 900 grants that a…